Literature DB >> 26123787

Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma.

K Harada1, S Ida1,2, Y Baba1, T Ishimoto1, K Kosumi1, R Tokunaga1, D Izumi1, M Ohuchi1, K Nakamura1, Y Kiyozumi1, Y Imamura1, M Iwatsuki1, S Iwagami1, Y Miyamoto1, Y Sakamoto1, N Yoshida1, M Watanabe2, H Baba1.   

Abstract

Recently, depletion of skeletal muscle mass (sarcopenia) has been linked to poor prognosis in several types of cancers, but has not been investigated in esophageal squamous cell carcinoma (ESCC). This retrospective study investigates the relationship between sarcopenia and clinical outcome in ESCC patients treated by surgical resection or definitive chemoradiation therapy (dCRT). The study was retrospectively conducted in a single academic hospital in Kumamoto, Japan, and involved 325 ESCC patients (256 surgical cases and 69 dCRT cases) treated between April 2005 and April 2011. Skeletal muscle mass was quantified by radiologic measures using standard computed tomography scans. The skeletal muscle tissue in the 325 ESCC patients was distributed as follows: mean: 47.10; median: 46.88; standard deviation (SD): 7.39; range: 31.48-71.11; interquartile range, 46.29-47.90. Skeletal muscle tissue was greater in male patients than in female patients (P < 0.0001), but was independent of other clinical and tumor features. Sarcopenia was not significantly associated with overall survival (log rank P = 0.54). Lymph node involvement significantly altered the relationship between sarcopenia and survival rate (P for interaction = 0.026). Sarcopenia significantly reduced the overall survival of patients without lymph node involvement (log rank P = 0.035), but was uncorrelated with overall survival in patients with lymph involvement (log rank, P = 0.31). The anastomosis leakage rate was significantly higher in the sarcopenia group than in the non-sarcopenia group (P = 0.032), but other surgical complications did not significantly differ between the two groups. Sarcopenia in ESCC patients without lymph node involvement is associated with poor prognosis, indicating sarcopenia as a potential biomarker for identifying patients likely to experience an inferior outcome. Moreover, sarcopenia was associated with anastomosis leakage but no other short-term surgical outcome.
© 2015 International Society for Diseases of the Esophagus.

Entities:  

Keywords:  esophageal squamous cell carcinoma (ESCC); nutrition; prognostic factor; sarcopenia

Mesh:

Year:  2015        PMID: 26123787     DOI: 10.1111/dote.12381

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  36 in total

1.  Preoperative controlling nutritional status (CONUT) is useful to estimate the prognosis after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Kazuto Harada; Yoshifumi Baba; Keisuke Kosumi; Masaaki Iwatsuki; Koichi Kinoshita; Kenichi Nakamura; Yasuo Sakamoto; Yuji Miyamoto; Ryuichi Karashima; Kosuke Mima; Hiroshi Sawayama; Mayuko Ohuchi; Akira Chikamoto; Yu Imamura; Masayuki Watanabe; Hideo Baba
Journal:  Langenbecks Arch Surg       Date:  2017-01-30       Impact factor: 3.445

Review 2.  The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.

Authors:  Hánah N Rier; Agnes Jager; Stefan Sleijfer; Andrea B Maier; Mark-David Levin
Journal:  Oncologist       Date:  2016-07-13

3.  Preoperative malnutrition and prognosis after neoadjuvant chemotherapy followed by subsequent esophagectomy.

Authors:  Naoya Yoshida; Yoshifumi Baba; Hideo Baba
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

4.  Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.

Authors:  Yohei Ozawa; Toru Nakano; Yusuke Taniyama; Tadashi Sakurai; Yu Onodera; Kurodo Kamiya; Makoto Hikage; Chiaki Sato; Kai Takaya; Takuro Konno; Michiaki Unno; Takashi Kamei
Journal:  Esophagus       Date:  2019-04-12       Impact factor: 4.230

5.  Opportunistic muscle measurements on staging chest CT for extremity and truncal soft tissue sarcoma are associated with survival.

Authors:  Eileen N Phan; Steven W Thorpe; Felix S Wong; Augustine M Saiz; Sandra L Taylor; Robert J Canter; Leon Lenchik; R Lor Randall; Robert D Boutin
Journal:  J Surg Oncol       Date:  2020-07-01       Impact factor: 3.454

Review 6.  F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.

Authors:  Ammar Sukari; Irfana Muqbil; Ramzi M Mohammad; Philip A Philip; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2016-01-21       Impact factor: 15.707

7.  Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?

Authors:  Hiroshi Saeki; Yuichiro Nakashima; Kensuke Kudou; Shun Sasaki; Tomoko Jogo; Kosuke Hirose; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Ryota Nakanishi; Nobuhide Kubo; Koji Ando; Akira Kabashima; Eiji Oki; Yoshihiko Maehara
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

8.  Sarcopenia and Short-Term Outcomes After Esophagectomy: A Meta-analysis.

Authors:  Pei-Yu Wang; Li-Dong Xu; Xian-Kai Chen; Lei Xu; Yong-Kui Yu; Rui-Xiang Zhang; Hai-Bo Sun; Hui-Li Wu; Yin Li
Journal:  Ann Surg Oncol       Date:  2020-02-10       Impact factor: 5.344

9.  Impact of Sarcopenia in Patients with Unresectable Locally Advanced Esophageal Cancer Receiving Chemoradiotherapy.

Authors:  Sho Sato; Chikara Kunisaki; Hideaki Suematsu; Yusaku Tanaka; Hiroshi Miyamoto; Takashi Kosaka; Norio Yukawa; Kuniya Tanaka; Kei Sato; Hirotoshi Akiyama; Itaru Endo
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

10.  Sarcopenia does not affect postoperative complication rates in oesophageal cancer surgery: a systematic review and meta-analysis.

Authors:  D Schizas; M Frountzas; I Lidoriki; E Spartalis; K Toutouzas; D Dimitroulis; T Liakakos; K S Mylonas
Journal:  Ann R Coll Surg Engl       Date:  2019-09-11       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.